Evidence map›Paper›PMID 38327440›Full record

ArticleHeliyon2024

Comparison of four different human papillomavirus genotyping methods in cervical samples: Addressing method-specific advantages and limitations.

Juliana D Siqueira, Brunna M Alves, Adriana B C Castelo Branco, Kristiane C D Duque, Maria Teresa Bustamante-Teixeira, Esmeralda A Soares, José Eduardo Levi, Gulnar Azevedo E Silva, Marcelo A Soares

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juliana D SiqueiraPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.
Brunna M AlvesPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.
Adriana B C Castelo BrancoPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.
Kristiane C D DuqueDiretoria de Ensino, Pesquisa e Extensão, Instituto Federal de Santa Catarina, Joinville, SC, Brazil.
Maria Teresa Bustamante-TeixeiraNúcleo de Assessoria, Treinamento e Estudos em Saúde, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.
Esmeralda A SoaresPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.
José Eduardo LeviInstituto de Medicina Tropical de São Paulo Medical School, Universidade de São Paulo, São Paulo, Brazil.
Gulnar Azevedo E SilvaDepartamento de Epidemiologia, Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Marcelo A SoaresPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since human papillomavirus (HPV) is recognized as the causative agent of cervical cancer and associated with anogenital non-cervical and oropharyngeal cancers, the characterization of the HPV types circulating in different geographic regions is an important tool in screening and prevention. In this context, this study compared four methodologies for HPV detection and genotyping: real-time PCR (Cobas® HPV test), nested PCR followed by conventional Sanger sequencing, reverse hybridization (High + Low PapillomaStrip® kit) and next-generation sequencing (NGS) at an Illumina HiSeq2500 platform. Cervical samples from patients followed at the Family Health Strategy from Juiz de Fora, Minas Gerais, Brazil, were collected and subjected to the real-time PCR. Of those, 114 were included in this study according to the results obtained with the real-time PCR, considered herein as the gold standard method. For the 110 samples tested by at least one methodology in addition to real-time PCR, NGS showed the lowest concordance rates of HPV and high-risk HPV identification compared to the other three methods (67-75 %). Real-time PCR and Sanger sequencing showed the highest rates of concordance (97-100 %). All methods differed in their sensitivity and specificity. HPV genotyping contributes to individual risk stratification, therapeutic decisions, epidemiological studies and vaccine development, supporting approaches in prevention, healthcare and management of HPV infection.

Indexed as

HPV genotypingHPV multiple infectionsNext-generation sequencingReal-time PCRReverse hybridizationSanger sequencing

Identifiers

PMID38327440
PMCPMC10847660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.